New combo therapy aims to slow advanced liver cancer
NCT ID NCT06485466
First seen Apr 22, 2026 · Last updated Apr 30, 2026 · Updated 1 time
Summary
This study tests whether adding a targeted drug (apatinib) and an immunotherapy (camrelizumab) to a standard liver cancer treatment (TACE) can better control cancer growth in people whose liver cancer cannot be removed by surgery. About 101 adults with intermediate or advanced liver cancer will be randomly assigned to receive either the triple combination or just the drug pair. The goal is to see if the triple therapy extends the time before cancer worsens.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for UNRESECTABLE HEPATOCELLULAR CARCINOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Sichuan Cancer Hospital and Research Institute
RECRUITINGChengdu, Sichuan, 610041, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.